The global newborn screening market was valued at USD 789.35 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.54% from 2023 to 2030. This growth is primarily driven by several factors, including an increasing neonatal population, a rising incidence of congenital diseases in newborns, heightened consumer awareness, and supportive initiatives from various governments that are implementing programs and legislations to promote newborn screening. Additionally, advancements in screening technologies are expected to further enhance market growth.
The growing prevalence of congenital diseases among newborns is anticipated to positively impact the newborn screening market. According to data released by the World Health Organization (WHO) in February 2023, approximately 240,000 newborns worldwide die within the first 28 days of life each year due to congenital conditions. These disorders are also linked to around 170,000 child deaths annually among those aged between one month and five years. Furthermore, research from Indian Pediatrics indicates that congenital hypothyroidism occurs in 2.1 out of every 1,000 infants in India, with the prevalence of inborn metabolic disorders ranging from 2% to 7.8%. The significant occurrence of congenital diseases in newborns is likely to drive the demand for testing, thereby accelerating market growth by 2030.
Gather more insights about the market drivers, restrains and growth of the Newborn Screening Market
Technology Insights
In 2022, the tandem mass spectrometry segment emerged as the dominant force in the newborn screening market, capturing 24.5% of the overall revenue share. This leadership position can be attributed to several key factors, including its cost-effectiveness, broader applicability across various testing scenarios, and continuous technological advancements. Tandem mass spectrometry (MS/MS) is particularly valued for its ability to efficiently diagnose a wide range of medical conditions in a single testing procedure, making it an invaluable tool in newborn screening.
The efficiency of tandem mass spectrometry allows healthcare professionals to conduct comprehensive screenings that can identify multiple disorders simultaneously, thereby facilitating timely interventions. As the healthcare landscape evolves, the demand for rapid and accurate diagnostic tools has surged. This trend is likely to propel the tandem mass spectrometry segment to experience substantial growth, with a significant compound annual growth rate (CAGR) projected over the coming years. The innovative advancements being made by key market players are also expected to contribute to this growth. For example, in April 2023, Waters Corporation unveiled its new Xevo TQ Absolute IVD Mass Spectrometer, designed specifically for clinical applications. This product exemplifies the continuous push for technological enhancements that not only improve diagnostic accuracy but also streamline laboratory workflows.
In addition to tandem mass spectrometry, the electrophoresis segment is anticipated to see notable demand, projecting an impressive CAGR of 8.09% throughout the forecast period. The increasing emphasis on early detection techniques in healthcare is a primary driver behind this growth. Early diagnosis is crucial in managing congenital diseases effectively, as it allows for timely treatment and better health outcomes for newborns. Consequently, as healthcare providers and institutions prioritize early intervention strategies, the demand for electrophoresis is expected to rise correspondingly.
The growth of the electrophoresis segment is further supported by a surge in collaborations among various market players. Such partnerships often lead to innovative solutions that enhance product offerings and broaden market reach. For instance, in October 2022, CMP Scientific Corp. entered into a co-marketing agreement with Agilent to promote its advanced electrophoresis system. This collaboration not only aims to improve the technological capabilities of electrophoresis solutions but also focuses on expanding accessibility to these crucial diagnostic tools in newborn screening programs.
Moreover, the increasing focus on research and development in the field of newborn screening technologies is set to further enhance the capabilities of both tandem mass spectrometry and electrophoresis. As new methodologies and products are introduced, healthcare providers will be better equipped to address the complexities associated with congenital diseases. The integration of advanced technologies is expected to foster innovation, leading to more efficient, reliable, and cost-effective solutions for newborn screening.
Order a free sample PDF of the Newborn Screening Market Intelligence Study, published by Grand View Research.